# Bioequivalence Study of Revolade® Eltrombopag 50 mg

> **NCT06834451** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Centro de Atencion e Investigacion Medica** · enrollment: 30 (estimated)

## Conditions studied

- Healthy
- Healthy Donors

## Interventions

- **DRUG:** Revolade®
- **DRUG:** Eltrombopag (EPAG)

## Key facts

- **NCT ID:** NCT06834451
- **Lead sponsor:** Centro de Atencion e Investigacion Medica
- **Sponsor class:** NETWORK
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-06-01
- **Primary completion:** 2025-10-30
- **Final completion:** 2025-10-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06834451

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06834451, "Bioequivalence Study of Revolade® Eltrombopag 50 mg". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06834451. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*